Physician profile
Roger E Jones
NPI 1457347379
$78,013.20
in general payments reported to CMS, 2019-2025
24 companies · $26K in 2025
The $26K reported for 2025 was more than what 99% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $687 · 2020: $227 · 2021: $363 · 2022: $560 · 2023: $25K · 2024: $26K · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $76K · Food and Beverage: $301.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $75,875.00 |
| Food and Beverage | $300.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Plasma INC. | $75,875.00 | 2023-2025 | |
| Lilly USA, LLC | $426.53 | 2019-2024 | Mounjaro |
| Abbvie INC. | $314.85 | 2020-2022 | |
| Glaxosmithkline, LLC. | $199.87 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $143.92 | 2021-2022 | |
| Radius Health, INC. | $124.74 | 2019 | |
| Novartis Pharmaceuticals Corporation | $120.87 | 2019 | |
| Novo Nordisk INC | $113.56 | 2019-2023 | |
| Lundbeck LLC | $106.53 | 2020-2023 | Abilify Maintena |
| Endo Pharmaceuticals INC. | $96.88 | 2021-2022 | |
| Amgen INC. | $94.74 | 2020-2023 | Otezla, Repatha |
| Mylan Specialty L.P. | $89.37 | 2019 | |
| Indivior INC. | $53.84 | 2022-2024 | Sublocade |
| Pfizer INC. | $52.56 | 2020-2023 | |
| Allergan, INC. | $34.53 | 2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $32.20 | 2021 | |
| Shield Therapeutics INC | $22.12 | 2022 | |
| Grifols USA, LLC | $19.85 | 2020 | |
| Abbott Laboratories | $18.18 | 2022 | |
| Merck Sharp & Dohme LLC | $17.35 | 2019 | |
| Masimo Corporation | $15.77 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $15.10 | 2020 | |
| Astrazeneca Pharmaceuticals Lp | $12.96 | 2020 | |
| Orexo US, INC. | $11.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roger Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.